5.3 C
New York
Tuesday, March 21, 2023

Are Things Looking Up For Takeda Pharmaceutical Company Limited (NYSE: TAK)?

After Hours

There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. After-hours trades for Takeda Pharmaceutical Company Limited (TAK) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.16, or 1.02%, to $15.80. The Takeda Pharmaceutical Company Limited has recorded 1,789 volume in the after hours trading session. Most recently, Yahoo Finance reported about the stock as it publicized that Takeda Presents Positive Results from Phase 3 Study of Vedolizumab for Prevention of Intestinal Acute Graft-Versus-Host Disease (aGvHD) in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT).

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".


Stocks Info

As a NYSE listed company, TAK falls under the Healthcare sector while operating within the Drug Manufacturers – Specialty & Generic industry segment. At the end of the last regular session, the stock closed at $15.64 and fluctuated between $15.76 as its day high and $15.62 as its day low. The current market capitalization of Takeda Pharmaceutical Company Limited is $48.69B. A total of 1.83 million shares were traded on the day, compared to an average of 2.82M shares.


Investors prefer companies that pay dividends because dividends generate immediate cash flow and indicate a positive outlook. Takeda Pharmaceutical Company Limited pays an annual dividend of $1.06, resulting in a dividend yield of 6.76%, and it has a price to earnings (P/E) ratio of 24.32.

In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. According to analysts who have offered 12-month price targets for TAK in the last 3 months, the mean price target is $17.82 with high estimates of $26.33 and low estimates of $14.12. In terms of 52-week highs and lows, TAK has a high of $16.30 and a low of $12.28.

As of this writing, TAK has an earnings estimate of $0 per share for the current quarter. EPS was calculated based on a consensus of 0 estimates, with a high estimate of $0 per share and a lower estimate of $0.

Balance Sheet Annually/Quarterly

The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects.

Analysts Opinion

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 14 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for TAK is Hold with a score of 3.67. A total of 5 analysts rated the stock as Buy while 0 rated it as Overweight while 9 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles